Weight change from incretin-based weight loss medications across categories of second-generation antipsychotics
Authors' conclusion
Semaglutide and tirzepatide induce weight loss among those prescribed SGAs, with lower effectiveness in those prescribed higher AIWG SGAs.
Study context
- Population
- Adults (≥18 years) without diabetes, prescribed second-generation antipsychotics (SGA) and eligible for incretin-based weight loss medications, June 2021-December 2023; mean age 51.9 years (SD: 17.7), mean BMI 39.5 kg/m² (SD: 7.7)analytic sample
- Participants
- 66,574 adults
- Exposure
- Incretin-based weight loss medications vs no prescription, by antipsychotic induced weight gain (AIWG) category of SGA
- Outcome
- Change in weight (kg) and probability of at least 5% weight loss
- Follow-up
- 6 months
Methodological detailselectronic health records (Epic Cosmos)
- Electronic health records (Epic Cosmos)
Main finding
As reported in the abstract
Weight change and ≥5% weight loss
Each group vs no prescriptionWeight change, kg (95% CI)
Incretin-based medications
−2.17(−2.49 to −1.84)
- Incretin-based medications
- times more likely to achieve 5% weight loss 1.71 (95% CI 1.63–1.80)
Observational data: associations, not effects.
Further findings
Weight change with incretin-based medications by AIWG category of SGA
- Low AIWG SGAs
- −3.02 kg, 95% CI: −3.29, −2.74
- High AIWG SGAs
- −1.33 kg, 95% CI: −2.04, −0.62
- Weight loss greater with low vs high AIWG SGAs
Original publication
Weight change from incretin-based weight loss medications across categories of second-generation antipsychotics. Int J Obes (Lond). Published 15 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →